Photopheresis

A process in which peripheral blood is exposed in an extracorporeal flow system to photoactivated 8-methoxypsoralen (METHOXSALEN) and ultraviolet light - a procedure known as PUVA THERAPY. Photopheresis is at present a standard therapy for advanced cutaneous T-cell lymphoma; it shows promise in the treatment of autoimmune diseases.

Also Known As:

Networked: 766 relevant articles (109 outcomes, 75 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1.	Knobler, Robert: 18 articles (02/2020 - 09/2002)
2.	Duvic, Madeleine: 12 articles (03/2022 - 01/2002)
3.	Fimiani, M: 12 articles (08/2013 - 10/2000)
4.	Rubegni, P: 12 articles (08/2013 - 10/2000)
5.	Perotti, Cesare: 11 articles (01/2022 - 07/2003)
6.	Edelson, Richard L: 11 articles (01/2020 - 02/2002)
7.	Del Fante, Claudia: 10 articles (01/2022 - 07/2003)
8.	Girardi, Michael: 10 articles (01/2019 - 02/2002)
9.	Knobler, R: 9 articles (01/2021 - 03/2001)
10.	Greinix, Hildegard T: 9 articles (01/2019 - 03/2006)

Related Diseases

1.	Graft vs Host Disease (Graft-Versus-Host Disease) 12/01/2019 - "Extracorporeal photopheresis (ECP) therapy has proved to be an effective and safe treatment for graft-versus-host-disease (GvHD), an important complication after hematopoietic stem cell transplantation. " 05/14/2010 - "Extracorporeal photopheresis (ECP) is an effective immunomodulatory therapy and has been demonstrated to be beneficial for graft-vs-host disease and solid-organ allograft rejection. " 07/01/2003 - "This study aimed to ascertain whether extracorporeal photochemotherapy (ECP) is an effective treatment for paediatric patients with refractory graft-versus-host disease (GVHD). " 10/01/2023 - "Extracorporeal photopheresis (ECP) is considered an effective treatment for patients with chronic graft vs host disease (cGVHD) and demonstrates efficacy in ameliorating GVHD. " 10/01/2022 - "Extracorporeal photopheresis (ECP) has been shown to be an effective treatment for graft-versus-host disease (GvHD). "
2.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 10/01/2002 - "Since photopheresis, a treatment that induces an anticlonotypic immune response, has proven to be effective in both cutaneous T cell lymphomas with circulating clonal T cells and in cGVHD, we have searched for circulating clonal T cell populations in patients with cGVHD, and determined whether T cell clonality in the blood is associated with therapeutic response. " 01/01/2014 - "After the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown significant promise in the treatment of other severe and refractory conditions in a multi-disciplinary setting. " 06/01/2004 - "Extracorporeal photochemotherapy (ECP), considered as an effective treatment for patients with erythrodermic cutaneous T-cell lymphoma (CTCL), has recently been used successfully in the treatment of GvHD. " 10/01/1996 - "Photopheresis appears to be effective for selected patients with erythrodermic cutaneous T-cell lymphoma, although we did not achieve as high a remission rate as previously reported by others." 07/01/2015 - "Extracorporeal photopheresis (ECP) alone or in combination therapy is effective for treatment of leukemic cutaneous T-cell lymphoma (L-CTCL), but its mechanism(s) of action remain unclear. "
3.	Bronchiolitis Obliterans Syndrome 03/01/2016 - "Extracorporeal photopheresis is an effective treatment for acute and chronic graft versus host disease without severe impairment of the recipient's immune system. " 10/01/2013 - "Extracorporeal photopheresis (ECP) is an effective treatment for both acute and chronic graft-versus-host disease (GVHD) in children and adults. " 01/01/2018 - "Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease." 02/01/2003 - "Extracorporeal photochemotherapy (ECP; photopheresis), an immunomodulatory therapy, has previously demonstrated promising results in treating chronic graft-versus-host disease (cGvHD). " 12/01/2011 - "Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study."
4.	Autoimmune Diseases (Autoimmune Disease) 12/01/1993 - "Photopheresis, comprising the treatment of lymphocytes by a combination of the light-activated drug methoxypsoralen and UVA irradiation, has been shown to be effective in the treatment of some other autoimmune disease. " 06/01/1993 - "Extracorporeal photochemotherapy, an immune-modulating form of therapy, has been shown to be effective in the treatment of autoimmune diseases. " 02/01/2000 - "Although several case reports and case series suggest efficacy for photopheresis in the treatment of autoimmune diseases, few controlled studies have been conducted to test this hypothesis. " 02/01/2000 - "After a decade of interest, multiple case reports, open trials, and one controlled study, the role of photopheresis in autoimmune disease remains to be established. " 04/01/1993 - "Additional conditions in which clinical studies have suggested a therapeutic role for photopheresis include certain autoimmune diseases and reversal of rejection of solid organ allografts. "
5.	Sezary Syndrome (Sezary Erythroderma) 01/01/2002 - "Over the last decade, extracorporeal photopheresis has been the only single treatment that has been shown to improve survival in patients with Sezary syndrome, although its true efficacy and place in combination therapy remain unclear. " 08/01/1996 - "In this study, we investigated the ability of extracorporeal photopheresis (ExP) and in vitro PUVA (8-methoxy-psoralen + ultraviolet A) therapy to induce apoptosis in peripheral blood mononuclear cells from Sezary syndrome patients and normal controls. " 01/01/2019 - "Successful treatment of Sezary syndrome with extracorporeal photopheresis - The first attempt in India." 04/01/2012 - "Extracorporeal photochemotherapy (ECP) is an effective treatment modality for patients with erythrodermic myocosis fungoides (MF) and Sezary syndrome (SS). " 09/01/1999 - "Furthermore, a 20%-25% complete response rate with photopheresis alone, or in combination with other biologic response modifiers, has been obtained at our institution among patients with Sezary syndrome. "

Related Drugs and Biologics

1.	Steroids
2.	Interferon-alpha (Interferon Alfa)
3.	Adrenal Cortex Hormones (Corticosteroids)
4.	Tacrolimus (Prograf)
5.	Methoxsalen (Oxsoralen)
6.	Methotrexate (Mexate)
7.	Immunosuppressive Agents (Immunosuppressants)
8.	Furocoumarins (Furanocoumarins)
9.	Azithromycin (Zithromax)
10.	dupilumab

Related Therapies and Procedures

1.	Therapeutics
2.	Photopheresis
3.	Immunomodulation
4.	Lung Transplantation
5.	Stem Cell Transplantation